.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

EP. 1: Challenges in the Treatment of CINV

July 17th 2017

EP. 2: Types of CINV

July 17th 2017

EP. 3: Classification of Emetogenicity of Chemotherapeutic Agents

July 17th 2017

EP. 4: Multidisciplinary Approach to Treating CINV

July 17th 2017

EP. 5: Patient Risk Factors in CINV

July 17th 2017

EP. 6: Patient Education Materials for CINV

July 17th 2017

EP. 7: Treating CINV Due to Immunotherapy and Targeted Therapy

July 17th 2017

EP. 8: Role of 5-HT3 Receptor Antagonists in Treating CINV

July 17th 2017

EP. 9: Role of NK1 Receptor Antagonists in Treating CINV

July 17th 2017

EP. 10: 5-HT3/NK1 Receptor Antagonist Combinations for CINV

July 17th 2017

EP. 11: Use of Olanzapine in CINV

July 17th 2017

EP. 12: Use of Dexamethasone in CINV

July 17th 2017

EP. 13: Unmet Needs in CINV

July 17th 2017